Unsafe
Not Aligned
Patient Risk:
High
Summary
Most claims are speculative about biosimilar development/launch timing and legal mechanisms and are not supported by any provided FDA-approved prescribing information excerpts. Only mechanism-level biology is tangentially related, but approved indications are not verifiable because Section 1 text is missing.
Category Scores
Accurate Statements
Unsupported Statements
As of 2026, multiple companies have been working on risankizumab biosimilars.
No provided FDA label section addresses biosimilar development by multiple companies or current status/timing.
Biosimilar launches usually hinge on whether key exclusivities and patents have expired or been cleared, including litigation that affects launch timing.
No provided label section discusses biosimilar launch determinants, exclusivities, patent clearance, litigation, or launch timing.
Even when an approval is granted, patent stay mechanisms or injunction risk can delay actual market entry depending on jurisdiction and legal posture.
No provided label section discusses patent stays/injunctions or how they affect market entry timing.
Risankizumab has additional approved uses depending on regulator and region.
No provided label content addresses regulator/region-dependent approved uses.
Biosimilar manufacturers typically target specific reference-product indications.
No provided label content addresses biosimilar manufacturer practices or indication targeting.
Extrapolation can affect how quickly biosimilar labeling can match the reference product.
No provided label content discusses biosimilar extrapolation or timelines for labeling alignment.
A risankizumab biosimilar approved news item might not automatically mean all Skyrizi-labeled indications are covered, especially in early launches.
No provided label content addresses biosimilar indication coverage completeness in early launches.
Biosimilar indication coverage may vary by indication and jurisdiction due to patent/clinical-program decisions.
No provided label content addresses jurisdictional variation in biosimilar indication coverage or the role of patents/clinical programs.
Contradictions
Important Omissions
Approved indication(s) and specific labeled uses of risankizumab/Skyrizi (Section 1 INDICATIONS AND USAGE content).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Claims focus on biosimilar launch/legal timing and coverage scope without support from the provided FDA label excerpts. While not directly describing clinical contraindications/dosing, such unsupported statements could mislead stakeholders about availability/coverage expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple claims are outside the scope of the provided FDA-approved prescribing information and are unsupported (biosimilar development/launch timing/legal mechanisms and coverage scope).
Suggested Improvement
Limit statements to information explicitly supported by the provided label excerpts (e.g., mechanism and labeled safety items shown). Remove or rephrase biosimilar market-entry/legal/timing and indication-coverage assertions unless the exact FDA label text for those topics is provided.